Synthesis of 4-thiophen-2′-yl-1,4-dihydropyridines as potentiators of the CFTR chloride channel

被引:27
作者
Cateni, Francesca [2 ]
Zacchigna, Marina [2 ]
Pedemonte, Nicoletta [3 ]
Galietta, Luis J. V. [3 ]
Mazzei, Marco T. [4 ]
Fossa, Paola [1 ]
Giampieri, Michele [1 ]
Mazzei, Mauro [1 ]
机构
[1] Dept Pharmaceut Sci, I-16132 Genoa, Italy
[2] Dept Pharmaceut Sci, I-34127 Trieste, Italy
[3] Ist Giannina Gaslini, Mol Genet Lab, I-16147 Genoa, Italy
[4] Dept Expt Med, I-16132 Genoa, Italy
关键词
Cystic fibrosis; CFTR; Dihydropyridine; Potentiators; CoMFA; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAINS; SMALL-MOLECULE CORRECTORS; CYSTIC-FIBROSIS; PROTEIN; 1,4-DIHYDROPYRIDINES; TRAFFICKING; ACTIVATORS; MUTATIONS; PROSPECTS;
D O I
10.1016/j.bmc.2009.10.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The gating of the CFTR chloride channel is altered by a group of mutations that cause cystic fibrosis. This gating defect may be corrected by small molecules called potentiators. Some 1,4-dihydropyridine (DHP) derivatives, bearing a thiophen-2-yl and a furanyl ring at the 4-position of the nucleus, were prepared and tested as CFTR potentiators. In particular, we evaluated the ability of novel DHPs to enhance the activity of the rescued Delta F508-CFTR as measured with a functional assay based on the halide-sensitive yellow fluorescent protein. Most DHPs showed an effect comparable to or better than that of the reference compound genistein. The potency was instead significantly improved, with some compounds, such as 3g, 3h, 3n, 4a, 4b, and 4d, having a half effective concentration in the submicromolar range. CoMFA analysis gave helpful suggestions to improve the activity of DHPs. (c) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7894 / 7903
页数:10
相关论文
共 27 条
[1]   The protease-antiprotease battle in the cystic fibrosis lung [J].
Balfour-Lynn, IM .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1999, 92 :23-30
[2]   Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening [J].
Bobadilla, JL ;
Macek, M ;
Fine, JP ;
Farrell, PM .
HUMAN MUTATION, 2002, 19 (06) :575-606
[3]  
Cuthbert AW, 2006, J ROY SOC MED, V99, P30
[4]   ALTERED CHLORIDE-ION CHANNEL KINETICS ASSOCIATED WITH THE DELTA-F508 CYSTIC-FIBROSIS MUTATION [J].
DALEMANS, W ;
BARBRY, P ;
CHAMPIGNY, G ;
JALLAT, S ;
DOTT, K ;
DREYER, D ;
CRYSTAL, RG ;
PAVIRANI, A ;
LECOCQ, JP ;
LAZDUNSKI, M .
NATURE, 1991, 354 (6354) :526-528
[5]   PROCESSING OF MUTANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS TEMPERATURE-SENSITIVE [J].
DENNING, GM ;
ANDERSON, MP ;
AMARA, JF ;
MARSHALL, J ;
SMITH, AE ;
WELSH, MJ .
NATURE, 1992, 358 (6389) :761-764
[6]  
Falsone G., 1997, Pharmaceutical and Pharmacological Letters, V7, P21
[7]   Green fluorescent protein-based halide indicators with improved chloride and iodide affinities [J].
Galietta, LJV ;
Haggie, PM ;
Verkman, AS .
FEBS LETTERS, 2001, 499 (03) :220-224
[8]  
GROOTENHUIS PDJ, 2009, Patent No. 20090105272
[9]  
HARROLD MW, 2002, FOYES PRINCIPLES MED, P551
[10]   MORPHOLOGICAL, BIOCHEMICAL, AND ELECTROPHYSIOLOGICAL CHARACTERIZATION OF A CLONAL CELL (H9C2) LINE FROM RAT-HEART [J].
HESCHELER, J ;
MEYER, R ;
PLANT, S ;
KRAUTWURST, D ;
ROSENTHAL, W ;
SCHULTZ, G .
CIRCULATION RESEARCH, 1991, 69 (06) :1476-1486